Literature DB >> 19248128

Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada.

Paul Brassard1, Anne-Marie Lowe, Sasha Bernatsky, Abbas Kezouh, Samy Suissa.   

Abstract

OBJECTIVE: To determine the risk of tuberculosis (TB) among a cohort of patients with rheumatoid arthritis (RA) in Quebec and assess whether this risk is associated with exposure to nonbiologic disease-modifying antirheumatic drugs (DMARDs).
METHODS: We studied a cohort of patients with RA identified from the Quebec provincial physician billing and hospitalization databases for 1980-2003. TB incidence rates were determined for the period 1992-2003 and compared with the general population, standardized for age and sex using the standardized incidence ratio (SIR). Conditional logistic regression was used in a nested case-control analysis to estimate the rate ratio (RR) of TB related to nonbiologic DMARD exposure during the year before the index date.
RESULTS: Of the 24,282 patients with RA in the cohort, 50 cases of TB were identified. The standardized incidence rate was 45.8 cases per 100,000 person-years compared with 4.2 cases per 100,000 person-years in the general population of Quebec (SIR 10.9, 95% confidence interval [95% CI] 7.9-15.0). The adjusted RR of TB was 2.4 (95% CI 1.1-5.4) with corticosteroid use and 3.0 (95% CI 1.6-5.8) with nonbiologic DMARD use.
CONCLUSION: The age- and sex-standardized incidence rate of TB in RA patients is 10 times that of the general population. At least some of this risk may be related to nonbiologic DMARD and corticosteroid therapies. Our data support the role of TB screening before initiation of any immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19248128     DOI: 10.1002/art.24476

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  24 in total

1.  Accuracy of pharmacy and coded-diagnosis information in identifying tuberculosis in patients with rheumatoid arthritis.

Authors:  Christina T Fiske; Marie R Griffin; Ed Mitchel; Timothy R Sterling; Carlos G Grijalva
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-04-24       Impact factor: 2.890

Review 2.  [Long-term glucocorticoid therapy : Is there a safe dosage?].

Authors:  C Strehl; F Buttgereit
Journal:  Internist (Berl)       Date:  2016-09       Impact factor: 0.743

3.  Low vaccination rates among patients with rheumatoid arthritis in a German outpatient clinic.

Authors:  Marco Krasselt; Jean-Philipp Ivanov; Christoph Baerwald; Olga Seifert
Journal:  Rheumatol Int       Date:  2016-11-22       Impact factor: 2.631

4.  High incidence of intolerance to tuberculosis chemoprophylaxis.

Authors:  Muhammad Haroon; Una Martin; Joe Devlin
Journal:  Rheumatol Int       Date:  2010-07-24       Impact factor: 2.631

5.  Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: a meta-analysis.

Authors:  Songshi Ni; Zhenxue Fu; Jing Zhao; Hua Liu
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

6.  Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.

Authors:  Yesim Ozguler; Gulen Hatemi; Serdal Ugurlu; Emire Seyahi; Melike Melikoglu; Sermin Borekci; Ersan Atahan; Gul Ongen; Vedat Hamuryudan
Journal:  Rheumatol Int       Date:  2016-10-03       Impact factor: 2.631

Review 7.  Infection Risk and Safety of Corticosteroid Use.

Authors:  Jameel Youssef; Shannon A Novosad; Kevin L Winthrop
Journal:  Rheum Dis Clin North Am       Date:  2015-10-24       Impact factor: 2.670

Review 8.  The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses.

Authors:  William G Dixon; Samy Suissa; Marie Hudson
Journal:  Arthritis Res Ther       Date:  2011-08-31       Impact factor: 5.156

9.  Risk of Tuberculosis in Children with Juvenile Idiopathic Arthritis: A Nationwide Population-Based Study in Taiwan.

Authors:  Yi-Chen Hsin; Lai-Zhen Zhuang; Kuo-Wei Yeh; Cheng-Wei Chang; Jorng-Tzong Horng; Jing-Long Huang
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

Review 10.  Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.

Authors:  Sherine E Gabriel; Kaleb Michaud
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.